샘플 요청 목록

 카트 문의
시장보고서
상품코드
1577492

세계의 POC(Point-of-Care) 감염증 진단 시장

Point-of-Care Infectious Disease Diagnostics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 287 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

전 세계 POC(Point-of-Care) 감염증 진단 시장, 2030년까지 53억 달러에 달할 것으로 전망

2023년 26억 달러로 추정되는 세계 POC(Point-of-Care) 감염증 진단 의약품 시장은 2023-2030년 동안 연평균 10.8% 성장하여 2030년에는 53억 달러에 달할 것으로 예상됩니다. 이 보고서에서 분석한 부문 중 하나인 측면 흐름 면역측정법은 CAGR 11.6%를 기록하여 분석 기간 종료 시점에 27억 달러에 도달할 것으로 예상됩니다. 플로우스루 검사법 분야의 성장률은 분석 기간 동안 CAGR 10.6%로 추정됩니다.

미국 시장 7억 1,130만 달러로 추정, 중국은 CAGR 14.8%로 성장 전망

미국의 POC(Point-of-Care) 감염증 진단 시장은 2023년 7억 1,130만 달러 규모에 달할 것으로 추정됩니다. 세계 2위의 경제 대국인 중국은 2030년까지 12억 달러의 시장 규모에 도달할 것으로 예상되며, 2023-2030년 분석 기간 동안 14.8%의 CAGR을 기록할 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 8.0%와 9.3%의 CAGR을 기록할 것으로 예상됩니다. 유럽에서는 독일이 8.5%의 CAGR로 성장할 것으로 예상됩니다.

세계 POC(Point-of-Care) 감염증 진단 시장 - 주요 동향 및 촉진요인 요약

POC(Point-of-Care) 감염증 진단이 의료 서비스 제공과 환자 결과를 변화시킬 수 있는 이유는 무엇인가?

POC(Point-of-Care) 감염증 진단은 환자 진료 현장 또는 그 근처에서 신속하고 정확한 분산형 감염 검사를 가능하게함으로써 헬스케어에 혁명을 일으키고 있습니다. 이러한 진단에는 측면 흐름 분석, 신속 항원 검사, 분자진단 분석, 면역분석 등 다양한 검사가 포함되며, 기존 검사실 밖에서 실시할 수 있어 의료진이 적시에 임상적 판단을 내릴 수 있는 중요한 정보를 얻을 수 있습니다. 집중적인 검사실과 전문 장비가 필요하고 검사 시간이 오래 걸리는 기존 진단법과 달리, POC 진단법은 몇 분에서 몇 시간 내에 결과를 얻을 수 있어 즉각적인 진단과 치료를 시작할 수 있습니다. 이러한 신속한 검사 능력은 HIV, 결핵, 독감, 성병(STI) 등 감염성 질환 관리에서 특히 중요하며, 조기 발견과 신속한 치료가 질병의 확산을 막고 환자의 예후를 개선하는 데 있어 매우 중요합니다.

POC 감염증 진단키트의 채택이 확대되고 있는 배경에는 특히 원격지나 자원이 부족한 지역, 의료 서비스가 부족한 지역에서 검사에 대한 접근성을 향상시킬 수 있다는 점이 있습니다. POC 진단제는 복잡한 검사 인프라를 필요로 하지 않기 때문에 지역 진료소나 지역 보건소, 심지어는 환자의 집에서도 검사를 시행할 수 있습니다. 이러한 접근성은 특히 의료 자원이 부족하고 감염병에 대한 부담이 큰 중저소득 국가에서 세계 보건 문제를 해결하는 데 있어 매우 중요합니다. 또한, POC 진단의 편의성과 사용 편의성은 환자의 순응도를 높이고 경과 관찰의 필요성을 줄여 보다 효율적인 의료 서비스 제공을 지원하여 의료 시스템의 부담을 줄일 수 있습니다. 신속하고 분산된 검사에 대한 수요가 지속적으로 증가함에 따라, POC 감염증 진단은 더 나은 질병 관리, 신속한 발병 대응, 더 효과적인 감염병 통제를 가능하게함으로써 세계 보건에서 점점 더 중요한 역할을 하고 있습니다.

어떤 기술 발전이 POC(Point-of-Care) 감염증 진단의 진화와 보급을 촉진하고 있는가?

기술의 발전은 POC(Point-of-Care) 감염증 진단의 정확성, 속도, 범용성을 크게 향상시켜 보다 효과적이고 광범위하게 적용될 수 있도록 하고 있습니다. 이 분야에서 가장 혁신적인 기술 혁신 중 하나는 중합효소 연쇄 반응(PCR), 등온증폭법 등의 기술을 이용하여 유전자 수준에서 병원체를 검출하는 분자 POC 진단법의 개발입니다. 분자진단법은 민감도와 특이도가 높아 환자 검체 내 낮은 수준의 병원체도 검출할 수 있습니다. 분자진단 플랫폼의 소형화와 랩온칩 기술의 통합으로 복잡한 분자 검사를 POC(Point-of-Care)에서 수행할 수 있게 되어 중앙 검사실에서 얻을 수 있는 결과에 필적하는 결과를 얻을 수 있게 되었습니다. 이러한 발전으로 분자 POC 진단은 세균, 바이러스, 진균을 포함한 광범위한 병원체 검출에 대한 분자 POC 진단의 활용이 확대되고 있으며, 하나의 샘플에서 여러 감염병을 동시에 식별하는 멀티플렉스 검사가 가능해졌습니다.

또 다른 중요한 기술 발전은 신속 항원 및 항체 검사의 개발로, 활동성 감염 및 병원체 노출 이력을 감지할 수 있는 결과를 즉각적으로 제공합니다. 일반적인 신속 항원 검사의 일종인 측면 흐름 분석(LFA)은 COVID-19, 독감, 말라리아, HIV와 같은 감염성 질환을 탐지하는 데 널리 사용되고 있습니다. 이 검사는 사용하기 쉽고 휴대가 간편하며 몇 분 안에 결과를 얻을 수 있도록 설계되어 임상 및 비임상 환경 모두에서 사용하기에 이상적입니다. 신호 감지 강화, 나노입자 라벨 사용 등 최근 측면 흐름 기술의 혁신은 이러한 검사의 민감도와 신뢰성을 향상시켜 질병 감시 및 지역 사회 검진 프로그램에서의 폭넓은 채택을 촉진하고 있습니다. 또한, 스마트폰 기반 판독 시스템을 갖춘 차세대 측면 흐름 분석법의 개발로 디지털 분석과 실시간 데이터 공유가 가능해지면서 POC(Point-of-Care) 진단을 디지털 헬스 플랫폼에 통합할 수 있는 여지가 더욱 커지고 있습니다.

디지털 기술과 인공지능(AI)의 통합은 POC(Point-of-Care) 감염증 진단의 진화를 더욱 촉진하고 있습니다. 디지털 POC 진단 제품은 검사 결과를 전자 의료 기록(EHR), 클라우드 기반 플랫폼 및 모바일 앱으로 전송하여 원격 모니터링 및 원격 건강 상담을 가능하게 하는 커넥티비티 기능으로 개발되고 있으며, AI 및 기계 학습 알고리즘을 사용하여 검사 결과 해석을 향상시키고 인간 오류 가능성을 줄여 임상의에게 실용적인 인사이트를 제공하고 있습니다. AI를 활용한 POC(Point-of-Care)는 질병 발생 예측 모델을 개발하고 POC(Point-of-Care) 워크플로우를 최적화하는 데에도 활용되고 있습니다. 디지털 기술과 AI의 결합은 보다 효율적인 데이터 수집, 분석 및 보고를 가능하게 하여 POC 진단을 공중보건 모니터링 및 역학 연구의 강력한 도구로 활용하고 있습니다. 기술의 발전과 함께 POC 감염증 진단은 더욱 정확하고 쉽게 사용할 수 있으며, 더 광범위한 의료 시스템과 통합되어 보다 효과적인 질병 관리 및 통제를 가능하게 할 것으로 기대됩니다.

시장 역학 및 규제 기준은 어떻게 점진적 감염증 진단 시장을 형성하고 있는가?

POC(point-of-care) 감염증 진단 시장은 시장 역학, 규제 기준, 헬스케어 동향의 복잡한 상호작용으로 인해 제품 개발, 채택, 상용화에 영향을 미치는 시장 역학이 형성되고 있습니다. 시장 촉진요인 중 하나는 선진국과 신흥국을 막론하고 감염성 질환의 확산으로 인해 신속하고 간편한 검사 솔루션에 대한 수요가 증가하고 있으며, HIV, 결핵, 간염, 말라리아 등 감염성 질환은 특히 진단 인프라가 부족한 중저소득 국가에서 전 세계적으로 심각한 보건 문제를 야기하고 있습니다. 심각한 보건 문제를 야기하고 있습니다. 최근 COVID-19 팬데믹은 신속하고 광범위한 검사의 필요성을 더욱 부각시켰으며, 발병 대응과 공중보건 관리에서 POC(Point-of-Care) 진단의 중요한 역할을 강조하고 있습니다. 전 세계 의료 시스템이 감염병을 더 잘 탐지하고 통제하기 위해 노력함에 따라, 신뢰할 수 있는 결과를 빠르고 효율적으로 제공할 수 있는 POC 진단에 대한 수요가 증가할 것으로 예상됩니다.

규제 기준과 컴플라이언스 요건도 POC(Point-of-Care) 감염증 진단 시장 형성에 중요한 역할을 하고 있습니다. 미국 식품의약국(FDA), 유럽의약품청(EMA) 및 기타 지역 기관과 같은 규제 기관은 진단 검사의 안전성, 유효성 및 신뢰성을 보장하기 위해 개발, 승인 및 상용화에 대한 엄격한 가이드라인을 제정하고 있습니다. 이러한 규제를 준수하는 것은 제조업체가 시장 진입을 달성하고 의료 제공자와 환자의 신뢰를 유지하는 데 필수적입니다. 특히 공중보건 비상사태에 대응하기 위한 POC(Point-of-Care) 진단의 신속한 개발 및 출시에 대응할 수 있도록 규제 환경은 진화하고 있습니다. 예를 들어, FDA의 긴급사용승인(EUA) 절차는 COVID-19 팬데믹 기간 동안 SARS-CoV-2 신속검사의 신속한 승인을 촉진하여 의료 및 지역사회에서 신속하게 배포 및 사용할 수 있도록 하는 데 널리 사용되었습니다. 다른 지역에서도 신종 감염병에 대한 POC 진단법 개발을 지원하기 위해 유사한 규제 경로가 검토되고 있습니다.

제조업체 간 경쟁, 기술 혁신, 헬스케어 리베이트 정책 등 시장 역학도 POC(Point-of-Care) 감염증 진단 시장에도 영향을 미치고 있습니다. 경쟁 환경의 특징으로는 기존 진단제 제조업체와 혁신적 스타트업이 존재하며, 각 업체는 우수한 성능, 사용 편의성, 경제성을 갖춘 새로운 POC 검사 솔루션을 개발하기 위해 노력하고 있습니다. 각 업체들은 제품 혁신, 전략적 파트너십, 기기, 시약, 디지털 헬스 통합을 포함한 종합적인 진단 솔루션 제공 능력을 통해 차별화를 꾀하고 있습니다. 특히 비용에 민감한 시장에서는 가격 압박이 심해지면서 품질 저하 없이 고성능을 제공하는 저가형 POC 검사에 대한 수요가 증가하고 있습니다. 또한, POC 검사 제품의 접근성 및 구매 용이성은 종종 상환에 의해 결정되는 경우가 많기 때문에 헬스케어 상환 정책 및 지불자의 보험 적용 범위 결정이 POC 검사 제품 도입에 영향을 미치고 있습니다. 지역마다 환급 환경은 크게 다르며, 검사의 임상적 유용성, 대체 진단 옵션의 존재 여부, 전체 의료 예산 등의 요인에 영향을 받습니다. 이러한 시장 역학 및 규제 기준을 잘 활용하는 것은 미충족 키워드 시장에서 사업을 운영하는 기업이 입지를 확장하고 전 세계 환자와 의료 서비스 제공자의 미충족 진단 수요를 충족시키기 위해 반드시 필요한 요소입니다.

POC(Point-of-Care) 감염증 진단 시장 확대를 촉진하는 주요 성장 요인은 무엇인가?

세계 POC(Point-of-Care) 감염증 진단 시장의 성장은 감염성 질환의 증가, 신속하고 분산된 검사 솔루션에 대한 수요 증가, 진단 기술의 발전 등 몇 가지 주요 요인에 의해 주도되고 있습니다. 주요 성장 요인 중 하나는 전 세계적으로 감염성 질환 유병률의 증가로 인해 조기 발견과 적시 치료를 위한 진단 도구에 대한 수요가 증가하고 있으며, HIV, 결핵, 간염, 성병(STI)과 같은 감염성 질환은 특히 중저소득 국가에서 공중보건에 큰 도전이 되고 있습니다. POC 진단제는 농촌 진료소, 지역 보건소, 재택 의료 환경과 같은 분산된 환경에서 신속하고 정확한 검사를 가능하게함으로써 이러한 문제를 해결하는 데 중요한 역할을 하고 있으며, POC 진단제는 치료 현장에서 신속하게 결과를 얻을 수 있어 환자의 검사 접근성을 향상시킬 수 있습니다. 환자의 검사 접근성을 향상시키고, 조기 진단을 가능하게 하며, 즉각적인 치료를 시작할 수 있도록 돕습니다.

또 다른 주요 성장 요인은 특히 COVID-19 팬데믹과 같은 세계 공중보건 비상사태에서 신속하고 분산된 검사 솔루션에 대한 관심이 높아지고 있다는 점입니다. 이번 팬데믹은 질병 확산을 억제하고 공중 보건을 관리하기 위해 확장 가능하고 쉽게 사용할 수 있는 진단 솔루션의 중요성을 부각시켰습니다. 복잡한 검사 인프라를 필요로 하지 않고 실시간으로 결과를 제공할 수 있는 POC(Point-of-Care) 진단은 COVID-19 및 기타 신종 감염병에 대응하는 데 필수적인 도구가 되었습니다. 이번 팬데믹 기간 동안 얻은 경험은 의료 시스템이 보다 강력하고 신속한 진단 역량을 구축하기 위해 노력하는 가운데, 다른 감염성 질환에 대한 POC 진단의 지속적인 채택을 촉진할 것으로 예상됩니다. 이러한 검사는 편의성이 뛰어나며, 기존의 의료 환경에서 질병 관리를 지원하기 때문에 재택 검사 및 자가 검사 옵션에 대한 수요 증가도 시장 성장에 기여하고 있습니다.

진단 기술의 발전은 POC(Point-of-Care) 감염증 진단 시장의 성장을 더욱 촉진하고 있습니다. 분자 POC 플랫폼, 디지털 진단, 커넥티비티와 같은 혁신은 더 높은 민감도, 특이성, 사용 편의성을 제공하는 검사 개발을 가능하게 하고 있으며, PCR 및 등온증폭과 같은 기술을 활용한 분자 POC 플랫폼은 박테리아, 바이러스, 곰팡이 등 다양한 병원체 검출을 위해 높은 정확도를 제공합니다. 스마트폰 기반 판독 시스템과 클라우드 연결을 갖춘 디지털 진단은 원격 모니터링 및 원격의료 플랫폼과의 통합을 통해 보다 종합적인 질병 관리 및 감시를 지원합니다. 단일 샘플에서 여러 병원체를 동시에 검출할 수 있는 멀티플렉스 POC 검사의 개발은 POC 진단의 능력을 확장하고 보다 범용적이고 효율적인 진단을 가능하게 하고 있습니다.

마지막으로, 신흥 시장에서 공중보건에 대한 관심과 진단 인프라 확충에 대한 관심이 높아지면서 POC(Point-of-Care) 감염증 진단 시장의 성장에 기여하고 있습니다. 아시아태평양, 아프리카, 라틴아메리카 등 감염성 질환의 부담이 크고 실험실 검사에 대한 접근성이 제한적인 지역에서는 POC(Point-of-Care)가 질병의 발견과 통제를 개선하는 솔루션을 제공하고 있습니다. 정부, 비영리 단체 및 국제 보건 기관은 의료 접근성을 강화하고 질병 부담을 줄이기 위해 진단 인프라와 지역 기반 검사 프로그램에 투자하고 있습니다. 이들 지역에서는 저렴한 가격의 POC(Point-of-Care) 진단 키트를 쉽게 구할 수 있어 검사의 광범위한 보급과 의료 성과 향상에 기여하고 있습니다. 공중보건, 일차의료, 재택의료 등 주요 부문의 수요가 지속적으로 증가하고, 제조업체들이 진화하는 의료 수요에 대응하기 위해 기술 혁신을 추진함에 따라 세계 POC(Point-of-Care) 감염증 진단 시장은 기술 발전, 응용 분야 확대, 신속하고 분산된 검사 솔루션에 대한 중요성 증가로 성장세를 보이고 있습니다. 기술 발전, 응용 분야 확대, 신속하고 분산된 검사 솔루션에 대한 중요성 증가에 힘입어 지속적인 성장이 예상됩니다.

조사 대상 기업 예시(총 38건)

  • AccuBioTech Co., Ltd.
  • Agilent Technologies, Inc.
  • BioFire Diagnostics LLC
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Cardinal Health, Inc.
  • Cepheid
  • Chembio Diagnostic Systems, Inc.
  • Danaher Corporation
  • EKF Diagnostics Holdings PLC

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 성장 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 24.10.29

Global Point-of-Care Infectious Disease Diagnostics Market to Reach US$5.3 Billion by 2030

The global market for Point-of-Care Infectious Disease Diagnostics estimated at US$2.6 Billion in the year 2023, is expected to reach US$5.3 Billion by 2030, growing at a CAGR of 10.8% over the analysis period 2023-2030. Lateral Flow Immunoassay Technique, one of the segments analyzed in the report, is expected to record a 11.6% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Flow-through Test Technique segment is estimated at 10.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$711.3 Million While China is Forecast to Grow at 14.8% CAGR

The Point-of-Care Infectious Disease Diagnostics market in the U.S. is estimated at US$711.3 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 14.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.0% and 9.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.5% CAGR.

Global Point-of-Care Infectious Disease Diagnostics Market - Key Trends & Drivers Summarized

Why Are Point-of-Care Infectious Disease Diagnostics Transforming Healthcare Delivery and Patient Outcomes?

Point-of-care (POC) infectious disease diagnostics are revolutionizing healthcare by enabling rapid, accurate, and decentralized testing of infectious diseases at or near the site of patient care. These diagnostics include a range of tests, such as lateral flow assays, rapid antigen tests, molecular diagnostic assays, and immunoassays, which can be performed outside traditional laboratory settings, providing healthcare providers with critical information for timely clinical decision-making. Unlike conventional diagnostic methods that require centralized laboratories, specialized equipment, and longer turnaround times, POC diagnostics deliver results within minutes to hours, allowing for immediate diagnosis and initiation of treatment. This rapid testing capability is particularly vital in the management of infectious diseases such as HIV, tuberculosis, influenza, and sexually transmitted infections (STIs), where early detection and prompt treatment are crucial to controlling disease spread and improving patient outcomes.

The growing adoption of POC infectious disease diagnostics is driven by their ability to increase access to testing, particularly in remote, resource-limited, and underserved areas. These diagnostics eliminate the need for complex laboratory infrastructure, making it possible to perform testing in rural clinics, community health centers, and even in patients’ homes. This accessibility is crucial for addressing global health challenges, especially in low- and middle-income countries where healthcare resources are limited and the burden of infectious diseases is high. Moreover, the convenience and ease of use of POC diagnostics enhance patient compliance and reduce the need for follow-up visits, supporting more efficient healthcare delivery and reducing the burden on healthcare systems. As the demand for rapid and decentralized testing continues to grow, POC infectious disease diagnostics are poised to play an increasingly important role in global health, enabling better disease management, faster outbreak response, and more effective control of infectious diseases.

What Technological Advancements Are Driving the Evolution and Adoption of Point-of-Care Infectious Disease Diagnostics?

Technological advancements are significantly enhancing the accuracy, speed, and versatility of point-of-care infectious disease diagnostics, making them more effective and widely applicable. One of the most transformative innovations in this field is the development of molecular POC diagnostics, which utilize techniques such as polymerase chain reaction (PCR) and isothermal amplification to detect pathogens at the genetic level. Molecular diagnostics offer high sensitivity and specificity, enabling the detection of even low levels of pathogens in patient samples. The miniaturization of molecular diagnostic platforms and the integration of lab-on-a-chip technologies are making it possible to perform complex molecular tests at the point of care, providing results that are comparable to those obtained in centralized laboratories. These advancements are expanding the use of molecular POC diagnostics for detecting a wide range of pathogens, including bacteria, viruses, and fungi, and are enabling multiplex testing to identify multiple infections simultaneously from a single sample.

Another significant technological advancement is the development of rapid antigen and antibody tests, which provide immediate results for detecting active infections or prior exposure to pathogens. Lateral flow assays (LFAs), a common type of rapid antigen test, are widely used for detecting infectious diseases such as COVID-19, influenza, malaria, and HIV. These tests are designed to be user-friendly, portable, and capable of delivering results within minutes, making them ideal for use in both clinical and non-clinical settings. Recent innovations in lateral flow technology, such as enhanced signal detection and the use of nanoparticle labels, are improving the sensitivity and reliability of these tests, supporting their broader adoption in disease surveillance and community screening programs. Additionally, the development of next-generation lateral flow assays with smartphone-based readout systems is enabling digital analysis and real-time data sharing, enhancing the integration of POC diagnostics into digital health platforms.

The integration of digital technologies and artificial intelligence (AI) is further driving the evolution of point-of-care infectious disease diagnostics. Digital POC diagnostics are being developed with connectivity features that allow them to transmit test results to electronic health records (EHRs), cloud-based platforms, or mobile apps, enabling remote monitoring and telehealth consultations. The use of AI and machine learning algorithms is enhancing the interpretation of test results, reducing the potential for human error, and providing actionable insights for clinicians. AI-driven POC diagnostics are also being used to develop predictive models for disease outbreaks and to optimize diagnostic workflows in field settings. The combination of digital technologies and AI is enabling more efficient data collection, analysis, and reporting, making POC diagnostics powerful tools for public health monitoring and epidemiological research. As technology continues to advance, POC infectious disease diagnostics are expected to become even more accurate, accessible, and integrated with broader healthcare systems, supporting more effective disease management and control.

How Are Market Dynamics and Regulatory Standards Shaping the Point-of-Care Infectious Disease Diagnostics Market?

The point-of-care infectious disease diagnostics market is shaped by a complex interplay of market dynamics, regulatory standards, and healthcare trends that are influencing product development, adoption, and commercialization. One of the primary market drivers is the increasing prevalence of infectious diseases, both in developed and developing regions, which is creating a growing demand for rapid and accessible testing solutions. Infectious diseases such as HIV, tuberculosis, hepatitis, and malaria continue to pose significant health challenges globally, particularly in low- and middle-income countries where diagnostic infrastructure is limited. The recent COVID-19 pandemic has further underscored the need for rapid and widespread testing, highlighting the critical role of POC diagnostics in outbreak response and public health management. As healthcare systems around the world strive to improve infectious disease detection and control, the demand for POC diagnostics that can deliver reliable results quickly and efficiently is expected to rise.

Regulatory standards and compliance requirements are also playing a crucial role in shaping the point-of-care infectious disease diagnostics market. Regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other regional bodies have established stringent guidelines for the development, approval, and commercialization of diagnostic tests to ensure their safety, efficacy, and reliability. Compliance with these regulations is essential for manufacturers to gain market access and maintain the trust of healthcare providers and patients. The regulatory landscape is evolving to accommodate the rapid development and deployment of POC diagnostics, particularly in response to public health emergencies. For example, the FDA’s Emergency Use Authorization (EUA) process, which was widely used during the COVID-19 pandemic, facilitated the expedited approval of rapid tests for SARS-CoV-2, enabling their rapid distribution and use in healthcare and community settings. Similar regulatory pathways are being explored in other regions to support the development of POC diagnostics for emerging infectious diseases.

Market dynamics such as competition among manufacturers, technological innovation, and healthcare reimbursement policies are also influencing the point-of-care infectious disease diagnostics market. The competitive landscape is characterized by the presence of established diagnostic companies and innovative startups, each striving to develop novel POC testing solutions that offer superior performance, ease of use, and affordability. Companies are differentiating themselves through product innovation, strategic partnerships, and the ability to provide comprehensive diagnostic solutions that include devices, reagents, and digital health integrations. Pricing pressures, particularly in cost-sensitive markets, are driving the demand for low-cost POC tests that offer high performance without compromising quality. Additionally, healthcare reimbursement policies and coverage decisions by payers are impacting the adoption of POC diagnostics, as reimbursement often determines the accessibility and affordability of these products. Reimbursement environments vary significantly across regions and are influenced by factors such as the clinical utility of the test, the availability of alternative diagnostic options, and the overall healthcare budget. Navigating these market dynamics and regulatory standards is essential for companies operating in the point-of-care infectious disease diagnostics market as they seek to expand their presence and address the unmet diagnostic needs of patients and healthcare providers worldwide.

What Are the Key Growth Drivers Fueling the Expansion of the Point-of-Care Infectious Disease Diagnostics Market?

The growth in the global point-of-care infectious disease diagnostics market is driven by several key factors, including the increasing prevalence of infectious diseases, the growing demand for rapid and decentralized testing solutions, and advancements in diagnostic technologies. One of the primary growth drivers is the rising incidence of infectious diseases worldwide, which is creating a significant need for diagnostic tools that can provide early detection and support timely treatment decisions. Infectious diseases such as HIV, tuberculosis, hepatitis, and sexually transmitted infections (STIs) continue to be major public health challenges, particularly in low- and middle-income countries. Point-of-care diagnostics are playing a critical role in addressing these challenges by enabling rapid and accurate testing in decentralized settings, such as rural clinics, community health centers, and home care environments. The ability of POC diagnostics to deliver results quickly and at the site of care is enhancing patient access to testing, supporting early diagnosis, and enabling immediate initiation of treatment, which is crucial for improving patient outcomes and reducing disease transmission.

Another significant growth driver is the increasing focus on rapid and decentralized testing solutions, particularly in the context of global health emergencies such as the COVID-19 pandemic. The pandemic has highlighted the importance of scalable and accessible diagnostic solutions for controlling disease spread and managing public health. POC diagnostics, with their ability to provide real-time results without the need for complex laboratory infrastructure, have become essential tools in the fight against COVID-19 and other emerging infectious diseases. The experience gained during the pandemic is expected to drive the continued adoption of POC diagnostics for other infectious diseases, as healthcare systems seek to build more resilient and responsive diagnostic capabilities. The growing demand for at-home and self-testing options is also contributing to market growth, as these tests offer convenience and support disease management in non-traditional healthcare settings.

Advancements in diagnostic technologies are further fueling the expansion of the point-of-care infectious disease diagnostics market. Innovations such as molecular POC platforms, digital diagnostics, and connectivity features are enabling the development of tests that offer higher sensitivity, specificity, and ease of use. Molecular POC platforms, which utilize techniques such as PCR and isothermal amplification, are providing highly accurate results for detecting a wide range of pathogens, from bacteria and viruses to fungi. Digital diagnostics with smartphone-based readout systems and cloud connectivity are enabling remote monitoring and integration with telehealth platforms, supporting more comprehensive disease management and surveillance. The development of multiplex POC tests, which can detect multiple pathogens simultaneously from a single sample, is also expanding the capabilities of POC diagnostics, making them more versatile and efficient.

Lastly, the increasing focus on public health initiatives and the expansion of diagnostic infrastructure in emerging markets are contributing to the growth of the point-of-care infectious disease diagnostics market. In regions such as Asia-Pacific, Africa, and Latin America, where the burden of infectious diseases is high and access to laboratory testing is limited, POC diagnostics are providing a solution for improving disease detection and control. Governments, non-profit organizations, and global health agencies are investing in diagnostic infrastructure and community-based testing programs to enhance access to care and reduce disease burden. The increasing availability of affordable POC diagnostics in these regions is supporting the broader adoption of testing and improving health outcomes. As demand from key sectors such as public health, primary care, and home healthcare continues to rise, and as manufacturers innovate to meet evolving healthcare needs, the global point-of-care infectious disease diagnostics market is expected to witness sustained growth, driven by advancements in technology, expanding applications, and the increasing emphasis on rapid and decentralized testing solutions.

Select Competitors (Total 38 Featured) -

  • AccuBioTech Co., Ltd.
  • Agilent Technologies, Inc.
  • BioFire Diagnostics LLC
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Cardinal Health, Inc.
  • Cepheid
  • Chembio Diagnostic Systems, Inc.
  • Danaher Corporation
  • EKF Diagnostics Holdings PLC

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Point-of-Care Infectious Disease Diagnostics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Focus on Early Diagnosis and Disease Prevention Drives Growth in Point-of-Care Infectious Disease Diagnostics Market
    • Increasing Adoption of Rapid Diagnostic Tests Expands Addressable Market for Point-of-Care Solutions
    • Case Overview: Growth in Global Infectious Disease Burden Bodes Well for Point-of-Care Diagnostics Market Expansion
    • Focus on Reducing Diagnostic Turnaround Time and Enhancing Patient Outcomes Strengthens Business Case for Market Adoption
    • Case Overview: Growth in Adoption of Point-of-Care Testing in Emergency and Critical Care Settings Expands Market Reach
    • Rising Focus on Infectious Disease Surveillance and Epidemiology Expands Market Opportunities
    • Increasing Use of Point-of-Care Diagnostics in Home Healthcare and Self-Testing Expands Market Scope
    • Case Overview: Growth in Digital Health Platforms and Telemedicine Drives Demand for Point-of-Care Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Point-of-Care Infectious Disease Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Point-of-Care Infectious Disease Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Lateral Flow Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Lateral Flow Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Lateral Flow Immunoassay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Flow-through Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Flow-through Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Flow-through Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Agglutination Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Agglutination Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Agglutination Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Techniques by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Home End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Home End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Home End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Assisted Living Healthcare Facilities End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Assisted Living Healthcare Facilities End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Assisted Living Healthcare Facilities End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • JAPAN
    • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • CHINA
    • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: China 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • EUROPE
    • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Point-of-Care Infectious Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • FRANCE
    • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: France 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 71: France Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: France 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • GERMANY
    • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Germany 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Italy 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 86: UK Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 89: UK Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: UK 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Spain 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 95: Spain Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Spain Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Spain 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Russia 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 101: Russia Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Russia Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Russia 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of Europe 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Europe Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Europe 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Asia-Pacific 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Australia 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 122: Australia Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Australia Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Australia 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • INDIA
    • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 125: India Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: India 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 128: India Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: India Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: India 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: South Korea 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 134: South Korea Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: South Korea Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: South Korea 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Asia-Pacific Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Asia-Pacific 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Latin America 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Argentina 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 155: Argentina Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Argentina Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Argentina 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Brazil 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 161: Brazil Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Brazil Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Brazil 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Mexico 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 167: Mexico Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Mexico Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Mexico 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Rest of Latin America 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Rest of Latin America Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Rest of Latin America 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Middle East 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Iran 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 188: Iran Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Iran Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Iran 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Israel 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 194: Israel Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Israel Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Israel 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Saudi Arabia 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Saudi Arabia Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Saudi Arabia 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: UAE 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 206: UAE Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: UAE Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: UAE 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Rest of Middle East 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Rest of Middle East Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Rest of Middle East 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • AFRICA
    • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Africa 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 218: Africa Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Africa Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Africa 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제